u/gallbladder_gary

Pharmacy margins and dispensing fees are regulated nationally, which explains price differences that otherwise look arbitrary.

a telehealth intake that asks nothing has told you what it is

Gallstones with rapid weight loss are common enough that it should be part of the standard briefing and it almost never is. Rapid loss changes bile composition; the mechanism is not mysterious and the incidence is not trivial.

Mine came out at month 7 and I would still do the whole thing again. But I would have liked to know it was on the list.

That is the catalogue certificate rather than the batch-specific one. Same layout, completely different status.

Careful — "the metadata looks odd" is a reason to ask a question, not a conclusion. Re-issues are ordinary.

A supply notice in one member state made the front page here and had no effect at all where I am.

Small fix — those two prices are for different pack sizes, which accounts for most of the gap.

redact your own name, never the batch details

salt forms are the recurring argument and the answer is boring

Related substances itemised individually is a much stronger document than a single total, because it tells you the shape of the impurity profile rather than its size.

redact your own name, never the batch details

The five questions worth asking before you commit to any compounded arrangement.

Which facility, by name. Whether it is a 503A pharmacy or a 503B outsourcing facility. What concentration is on the label. What the beyond-use date is based on. Whether there is potency testing on the finished preparation rather than only on the starting material.

All five are answerable in one email and the pattern of what comes back is more informative than any of the individual answers. An organisation with a quality system finds these questions ordinary.

The PDF creation date being later than the analysis date is usually a re-issue or a re-export. It is worth one question and it is not evidence of anything on its own.

a total of 0.4% tells you less than four named impurities adding to 0.6%

The PDF creation date being later than the analysis date is usually a re-issue or a re-export. It is worth one question and it is not evidence of anything on its own.

Correction: patient-specific refers to the prescription, not to a bespoke formulation. Common misreading and it changes the argument.

Agreed that pharmacy margin regulation explains a lot of the price differences people find mysterious.

HPLC-UV and LC-MS answer different questions

What is the beyond-use date and what is it based on?

Who is the prescriber, and are they the same organisation as the pharmacy?

Did they name the facility?

UV at 214nm sees the peptide bond and picks up almost everything; at 280nm you are looking at aromatics only. Which wavelength the number came from is part of the number.

HPLC-UV and LC-MS answer different questions

My first certificate had a compound name, a percentage and a logo. I thought that was normal. It is not, and now I know what to ask for.

Cross-border prescription recognition exists under EU rules but is conditional and narrower than commonly assumed, with requirements about the prescri

Adding the practical step — read your own country’s published criteria. They exist and they are definitive.

LC-MS gives you identity; UV purity gives you a relative quantity. A document with the first and not the second, or the reverse, is answering half the question.

axis labels included, always

Did they name the facility?

mikkel_correia is right about the concentration trap. It breaks arithmetic that has been reliable for months.

I would not read the price difference as a quality signal. Most of it is the consultation model, not the vial.

Same view.

This is the distinction the whole board runs on. Everything else follows from it.

redact your own name, never the batch details

Yes. The shortage list is the legal hinge for the whole arrangement and its status is public.

reimbursement is national, not European, and that is the whole board

Adding the practical step — read your own country’s published criteria. They exist and they are definitive.

Why the same vial can honestly produce three different numbers.

Purity by area percent is relative to what the detector saw on one gradient at one wavelength. Net peptide content subtracts counterion, water and residual solvent. Mass of peptide per vial is net content times fill weight, and fill weight has its own tolerance.

So a document reading 99% purity, 6% acetate and 4% water is describing a vial that is about 90% peptide by mass, and every one of those numbers is honest. The mistake is treating the headline figure as the answer to "how much peptide did I get".

The translation cost of dealing with a foreign pharmacy was the thing I had not budgeted for.

What did the intake actually ask you?

ismael_pires is right about the concentration trap. It breaks arithmetic that has been reliable for months.

EU-wide advice is almost always wrong somewhere

redact your own name, never the batch details

That is not what the method line says. It names the technique; it does not certify the operator.

That figure is the starting material purity, not the finished preparation potency. Two different tests.